Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
32.94
+0.33 (1.01%)
At close: Aug 4, 2026, 4:00 PM EDT
33.29
+0.35 (1.06%)
Pre-market: Aug 5, 2026, 7:35 AM EDT

Viking Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-560.02-393.34-150.92-100.83-70.36-55.68
Net Income
-534.8-359.64-109.96-85.9-68.87-54.99
Earnings Per Share
-4.66-3.19-1.01-0.91-0.90-0.71
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
501.66705.74902.61362.08155.49202.1
Total Debt
4.090.141.121.261.560.03
Net Cash (Debt)
497.58705.6901.49360.82153.92202.07
Net Cash Growth
-38.33%-21.73%149.85%134.42%-23.83%-18.53%
Net Cash Per Share
4.346.268.273.822.002.62

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-418.44-278.69-87.79-73.38-48.4-47.59
Free Cash Flow
-418.44-278.69-87.79-73.38-48.4-47.59
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.